Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
…, JR Brahmer, NE Ready, DE Gerber… - The lancet …, 2017 - thelancet.com
Background Nivolumab has shown improved survival in the treatment of advanced non-small-cell
lung cancer (NSCLC) previously treated with chemotherapy. We assessed the safety …
lung cancer (NSCLC) previously treated with chemotherapy. We assessed the safety …
[HTML][HTML] Five-year outcomes from the randomized, phase III trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non–small-cell lung …
…, S Antonia, M Wohlleber, DE Gerber… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE Immunotherapy has revolutionized the treatment of advanced non–small-cell lung
cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057), nivolumab …
cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057), nivolumab …
The invention of ethnicity: A perspective from the USA
KN Conzen, DA Gerber, E Morawska… - Journal of American …, 1992 - JSTOR
SINCE THE UNITED STATES has received recurring waves of mass immigration, a persistent
theme of American history has been that of the incorporation of the foreign born into the …
theme of American history has been that of the incorporation of the foreign born into the …
Constitutionalizing the economy: German neo-liberalism, competition law and the “new” Europe
DJ Gerber - The American Journal of Comparative Law, 1994 - academic.oup.com
In the years immediately following the end of the Second World War the prospects for economic
and political freedom in Europe seemed bleak. Many informed observers saw Europe's …
and political freedom in Europe seemed bleak. Many informed observers saw Europe's …
Designing-in performance: A framework for evolutionary energy performance feedback in early stage design
Multidisciplinary design optimization (MDO) has been identified as a potential means for
integrating design and energy performance domains but has not been fully explored for the …
integrating design and energy performance domains but has not been fully explored for the …
[HTML][HTML] Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer
…, H Lena, E Poddubskaya, DE Gerber… - … England Journal of …, 2015 - Mass Medical Soc
Background Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint–inhibitor
antibody, disrupts PD-1–mediated signaling and may restore antitumor immunity. …
antibody, disrupts PD-1–mediated signaling and may restore antitumor immunity. …
[HTML][HTML] Subregion-and cell type–restricted gene knockout in mouse brain
Using the phage P1–derived Cre/loxP recombination system, we have developed a method
to create mice in which the deletion (knockout) of virtually any gene of interest is restricted to …
to create mice in which the deletion (knockout) of virtually any gene of interest is restricted to …
[BOOK][B] Law and competition in twentieth century Europe: protecting Prometheus
DJ Gerber - 1998 - books.google.com
… David Gerber is professor of law and co-director of the International and Comparative Law
Programme at Chicago-Kent College of Law (Illinois Institute of Technology). He has been a …
Programme at Chicago-Kent College of Law (Illinois Institute of Technology). He has been a …
[HTML][HTML] Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
…, LC Cappelli, FB Cortazar, DE Gerber… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers.
While these immunotherapies have improved patient outcomes in many clinical settings…
While these immunotherapies have improved patient outcomes in many clinical settings…
Consolidative radiotherapy for limited metastatic non–small-cell lung cancer: a phase 2 randomized clinical trial
P Iyengar, Z Wardak, DE Gerber, V Tumati… - JAMA …, 2018 - jamanetwork.com
Importance Patterns-of-failure studies suggest that in metastatic non–small-cell lung cancer (NSCLC)
sites of gross disease at presentation are the first to progress when treated with …
sites of gross disease at presentation are the first to progress when treated with …